Euvic UK’s Post

I’ve just made my first stock investment, guided by our cutting-edge work at Gordion! Our Machine Learning platform, which typically helps pharma companies evaluate drug targets and identify likely responders, has an interesting unforeseen benefit: it can predict the outcomes of existing clinical trials. By training on trials with known outcomes, we’ve noticed a clear pattern - successful trials have dramatically high cohort-specific drug target essentiality, while failed ones do not. One standout example is trial NCT06005974, initiated for MEK inhibitor - congratulations Recursion. Inspired by these results, I decided to “put my money where my mouth is” and invest based on our technology predictions. Over the coming months, we’ll be collecting data from the outcomes of these predictions - the closest we can get to bringing our program to the clinic. Stay tuned for updates as we embark on this unexpected journey! 🚀 #InvestmentJourney #MachineLearning #ClinicalTrials #Biotech #AI

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital

Heading to #BioIT2024? Catch my session on April 16, 4:00-4:15 PM. I'll be discussing "Bridging Data and Discovery: Leveraging High-Quality, High-Volume Biomedical Datasets". Expect some examples and insights on making the process faster and more cost-effective. Also, check out our April 15 session, 2:20-2:50 PM, on "Accelerating Drug Discovery with Comprehensive Curated Knowledge". We'll showcase how knowledge graphs in Neo4j can unlock new potentials in drug discovery. If you're at the conference, I'd love to connect! Let’s discuss innovations in biotech or dive into the specifics of these technologies. #BioITWorld #DrugDiscovery #MachineLearning

Li Lin, founder and chairman of Haosi Biotech recently talked to CYZone, a media outlet focusing on China's startup ecosystem. Over the past eight years, Haosi Biotech has been committed to providing comprehensive clinical mass spectrometry solutions based on multi-omics research, growing from a laboratory to a company with annual revenues in the hundreds of millions. When discussing her initial rationale for choosing the mass spectrometry detection market, the member of the Alzheimer's Association, and former assistant professor at Tsinghua University and Medical University of Vienna expressed that laboratory technology is rapidly iterating. Assisting in the application of new technologies can enable science to benefit all people, and transformation is also a part of doing more practical science. She also shared the company's product development strategy, which involves manufacturing according to market demand, producing single or fixed application scenario testing instruments, and providing a complete set of solutions to give doctors more data and support. This series of market-oriented practices has made Haosi Biotech's equipment widely welcomed in the industry. #QMportfolio #QMhealthcare#spectrometry #HaosiBiotech #InnovationInBiotech #QimingVenturePartners #TsinghuaPekingUniversity #LifeScience 

I am currently on my way to the Scottish Life Sciences Summit 2024, which is taking place in Aberdeen on March 20th. This is my first time attending this event, and I'm excited to see what it has in store. The summit promises to bring together investors, entrepreneurs and other industry leaders to explore how to transform innovative ideas into commercial realities. The main topics for discussion this year include: ➡️ Unlocking the power of genetic data ➡️ Exploring the future of AI and its applications in biotech ➡️ Understanding how venture capitalists make their investment choices in life sciences One of the hot topics expected to be discussed at the event is the use of AI to accelerate drug discovery, which is why I am eager to be there 😊 Have you had the opportunity to attend this forum before? #lifescience #clinicaldevelopment #biotech

Pierre Socha, Amadeus Partner, puts the biotech public markets under the microscope in this European Life Sciences Review article🔬 Despite biotech IPO challenges, venture capital is fuelling innovation in AI and synthetic biology, with the latter poised to become a $30 billion industry by 2026. This surge is transforming healthcare delivery, making it more accessible outside conventional hospitals. We're proud to support these groundbreaking innovations, delivered by the pioneering founders we back 🤝 Read the article here⬇️ https://bit.ly/3z4HmRR #LifeSciences #HealthTech #VentureCapital

Wednesday July 24th, 8-9.30am PT. USA-UK-ANGELS: Online: Register here: https://lnkd.in/gvjDPmkU A collection of British linked startups, either based in UK or by British educated or UK citizen founders.8:10 - 8:25 AlgoDynamix: AlgoDynamix is a pioneer of behavioural-based price forecasting for the financial markets. 8:25-8:40 Lúnasa Space: Lúnasa is building enabling technologies for space infrastructure services, and in-space testbeds 8:40 - 8:55 Ani Biome: Ani Biome developed a machine learning architecture for non-invasive digital diagnostics and personalization of liquid fermented bioactives, AgeBiotics. 8:55 - 9:10 Oxford Drug Design: Oxford is a pre clinical therapeutics with distinctive GenAI drug discovery platform (SynthAI) overcomes inefficiency limitations of current methods and accelerates the potential impact for patients.

At the annual Decoding Bio summit, I sat down with Brad Loncar of BiotechTV to discuss how we at Bessemer Venture Partners are thinking about where value accrues for AI in biotech. The short answer: Ultimate value accrues at the therapeutic level. Longer answer: If AI improves drug discovery along any axis (speed, efficiency, cost, new biology, novel chemistry), and becomes a near-ubiquitous tool in the discovery process, value will accrue up the stack. Vertical integration of discovery and development will be essential to capture this value, and the greatest moats will (still) be built in clinical development – trial design, biomarker identification, indication selection, and raw execution.

Planning to attend the Translational Science Summit by LifeArc? 🌐 Our Biotech Venture Developer, Ankita Das, will be attending the “Translational Science Summit” tomorrow, the 23rd of April, in London. This event will bring together leading scientists, policy makers and innovators to discuss vital topics, such as navigating the funding in biotech ventures, data-driven discoveries, translational science, and accelerating translation for disadvantaged individuals. Don’t miss out to connect with Ankita, to hear more about our biotech projects! #TranslationalScienceSummit  #BiotechVentures #TranslationalScience #LifeArc

Last month, Michael Chen, our CEO, participated in a thought-provoking panel at HLTH Europe titled "Thrills, Pills, & VC Bills: What Will it Take to Unleash Innovation in the World of Drug Development?". The panel explored the integration of advanced technologies like artificial intelligence, high-throughput screening, and computational modeling in drug development. These innovations are revolutionizing the identification of potential drug candidates and the prediction of their efficacy and safety profiles, bringing rapid innovation closer to reality.  🚀 Key takeaways from the panel include: ● The transformative role of AI in accelerating drug discovery and optimizing clinical trials. ● The impact of high-throughput screening in reducing initial testing times. ● The potential of computational models to streamline preclinical and clinical phases. The importance of technologies like eProtein Discovery for accelerating protein production, a critical step in drug development. Michael, along with Karen Madden (Merck Life Science), Geraldine O'Keeffe (EQT Partners), and Ignacio H. Medrano (SAVANA), emphasized the importance of collaboration and the need for increased investment to support innovative projects.  #HLTHEurope #proteinacess